In plain language
During chronic total occlusion percutaneous coronary intervention (PCI), interventional cardiologists received notable eye and extremity doses, highest at the left eye, and radioprotective drapes lowered upper-limb and eye dose by about 28-49%. These are dose measurements, not health outcomes.
At a glance
- Type of study
- Original research, Dosimetry measurement study
- Who was studied
- Interventional cardiologists, Patients
- Size
- n = 65 procedures
- Summary based on
- the abstract
What it found
Radioprotective drapes reduced cardiologist exposure to upper limbs and eyes, especially on the left side.
Key figures: -28 to -49%
Cardiologist extremity doses per chronic total occlusion (CTO)-PCI procedure were of concern, particularly to the left eye.
Key figures: median 25-465 μSv; left eye median 68 μSv, max 187 μSv
Patient maximum skin dose was high, exceeding 2 Gy in a third of patients.
Key figures: median 1254 mGy; max 6528 mGy; >2 Gy in 33%
Limits to keep in mind
Single-series dosimetry study with a modest number of procedures (65 for staff dose, 31 with drapes) and non-randomized comparison; abstract only, with country and number of cardiologists not reported.
Related research summaries
- Radiation protection practices in diagnostic and interventional cardiology: Position paper from Portuguese Association of Interventional Cardiology (2025, Guideline or consensus statement)
- Radiation Exposure, Training, and Safety in Cardiology (2024, Narrative review)
- NCRP Commentary 26 - Guidance on Radiation Dose Limits for Lens of Eye (2016, Guideline or consensus statement)
- Radiation-Induced Noncancer Risks in Interventional Cardiology: Optimisation of Procedures and Staff and Patient Dose Reduction (2013, Narrative review)
- IU Health Handbook of Fluoroscopy Safety (Guideline or consensus statement)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.